VOLIBRIS (ambrisentan)


Pulmonary Arterial Hypertension (PAH)

Volibris is used to treat patients with pulmonary arterial hypertension (PAH) to improve exercise capacity (the ability to carry out physical activity).

PAH is abnormally high blood pressure in the arteries of the lungs. Volibris is used in patients with class II or III disease. The ‘class’ reflects the seriousness of the disease: ‘class II’ involves slight limitation of physical activity and ‘class III’ involves marked limitation of physical activity. Volibris has been shown to be effective in PAH with no identified cause and in PAH caused by connective tissue disease.

Because the number of patients with PAH is low, the disease is considered ‘rare’, and Volibris was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 11 April 2005.

Source: www.ema.europa.eu

Summary of the European Public Assessment Report (EPAR): 

Back to Catalogue of Drugs for Rare Diseases